abstract |
The present invention provides, for example, a pharmaceutical formulation for oral administration comprising H 376/95, sodium dodecyl sulphate (SDS) and a polymer selected from the group comprising hydroxypropyl methylcellulose (HPMC), hydroxyethyl cellulose (HEC) and polyoxyethylene oxide (PEO), a process for the preparation of such a formulation and the medical use of the formulation in the treatment of thromboembolism. |